A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients.
Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests.
Ali McBride, PharmD, and Paula Anastasia, RN, MN, AOCN, discuss how results from germline and somatic HRD testing help provide new options for patients with ovarian cancer. This approach has been a “game changer” in clinical outcomes for these patients.
Amina Ahmed, MD, MS, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, MS, discuss the importance of genetic testing in the workup of patients with ovarian cancer, including both germline and somatic testing. The experts consider practice guidelines and results of recent clinical trials and their perspectives on the impact of genetic testing on treatment as well as clinical outcomes.
Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients.
Dr Andrey Antov sees much potential for navigators when it comes to applying genetic and genomic testing to cancer care.
Dr Andrey Antov expands on how the healthcare team can work together to provide the best possible care for their patient.
Dr Andrey Antov recognizes how important the role of the navigator is in dealing with genetic and genomic testing, as the navigator often needs to help the patient gain access to the appropriate therapy, work with different stakeholders, monitor data, and more.
Dr Andrey Antov believes it's important for patients to participate in clinical trials for a multitude of reasons, as clinical trials can benefit both the patient and the healthcare system as a whole.
Dr Andrey Antov provides an overview of the role of Jackson Laboratory in the field of cancer genetic testing and in the education of nurses and navigators who co-manage patients at high risk or with a diagnosis of cancer.
Page 4 of 6
Results 31 - 40 of 57
Results 31 - 40 of 57